NASDAQ: BLFS | Healthcare / Medical Devices & Instruments / USA |
13.59 | -0.1100 | -0.80% | Vol 286.58K | 1Y Perf -44.89% |
Oct 4th, 2023 16:00 DELAYED |
BID | 12.97 | ASK | 14.21 | ||
Open | 13.71 | Previous Close | 13.70 | ||
Pre-Market | - | After-Market | 13.59 | ||
- - | - -% |
Target Price | 30.57 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 124.95 | Finscreener Ranking | ★★★★ 52.58 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★ 51.24 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★ 52.65 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 18.95 | Earnings Rating | Strong Sell | |
Market Cap | 591.03M | Earnings Date | 8th Nov 2023 | |
Alpha | 0.00 | Standard Deviation | 0.19 | |
Beta | 1.60 |
Today's Price Range 13.4913.71 | 52W Range 10.4826.89 | 5 Year PE Ratio Range -35.60-13.70 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Sell |
Performance | |||
---|---|---|---|
1 Week | -3.27% | ||
1 Month | 0.30% | ||
3 Months | -33.38% | ||
6 Months | -31.26% | ||
1 Year | -44.89% | ||
3 Years | -53.20% | ||
5 Years | -0.29% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -2.62 | |||
ROE last 12 Months | -25.24 | |||
ROA (5Y Avg) | -0.69 | |||
ROA last 12 Months | -21.60 | |||
ROC (5Y Avg) | -9.77 | |||
ROC last 12 Months | -21.42 | |||
Return on invested Capital Q | -2.24 | |||
Return on invested Capital Y | -2.83 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 4.50 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-7.50 | ||||
1.94 | ||||
7.36 | ||||
176.90 | ||||
-35.60 | ||||
-0.41 | ||||
7.25 | ||||
9.55 | ||||
775.96M | ||||
Forward PE | 197.28 | |||
PEG | -0.75 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
2.50 | ||||
3.70 | ||||
0.09 | ||||
0.11 | ||||
-13 244.70 | ||||
Leverage Ratio | 1.20 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
29.70 | ||||
-28.50 | ||||
-17.00 | ||||
-43.90 | ||||
-76.24 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
117.50M | ||||
2.75 | ||||
74.36 | ||||
66.74 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | -0.02 | -0.24 | -1 100.00 |
Q01 2023 | -0.10 | -0.27 | -170.00 |
Q04 2022 | -0.16 | -0.19 | -18.75 |
Q03 2022 | -0.12 | -0.15 | -25.00 |
Q02 2022 | -0.19 | -0.13 | 31.58 |
Q01 2022 | -0.13 | -0.19 | -46.15 |
Q04 2021 | -0.07 | -0.32 | -357.14 |
Q03 2021 | 0.02 | -0.19 | -1 050.00 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
9/2023 QR | -0.25 | -725.00 | Negative |
12/2023 QR | -0.20 | -433.33 | Negative |
12/2023 FY | -1.02 | -121.74 | Negative |
12/2024 FY | 0.07 | -63.16 | Negative |
Next Report Date | 8th Nov 2023 |
Estimated EPS Next Report | -0.25 |
Estimates Count | 2 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 286.58K |
Shares Outstanding | 43.49K |
Shares Float | 34.79M |
Trades Count | 5.53K |
Dollar Volume | 3.90M |
Avg. Volume | 449.79K |
Avg. Weekly Volume | 417.15K |
Avg. Monthly Volume | 484.69K |
Avg. Quarterly Volume | 447.52K |
BioLife Solutions Inc. (NASDAQ: BLFS) stock closed at 13.59 per share at the end of the most recent trading day (a -0.8% change compared to the prior day closing price) with a volume of 286.58K shares and market capitalization of 591.03M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 158 people. BioLife Solutions Inc. CEO is Michael Rice.
The one-year performance of BioLife Solutions Inc. stock is -44.89%, while year-to-date (YTD) performance is -25.33%. BLFS stock has a five-year performance of -0.29%. Its 52-week range is between 10.48 and 26.89, which gives BLFS stock a 52-week price range ratio of 18.95%
BioLife Solutions Inc. currently has a PE ratio of -7.50, a price-to-book (PB) ratio of 1.94, a price-to-sale (PS) ratio of 7.36, a price to cashflow ratio of 176.90, a PEG ratio of -0.75, a ROA of -21.60%, a ROC of -21.42% and a ROE of -25.24%. The company’s profit margin is -76.24%, its EBITDA margin is -17.00%, and its revenue ttm is $117.50 Million , which makes it $2.75 revenue per share.
Of the last four earnings reports from BioLife Solutions Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.25 for the next earnings report. BioLife Solutions Inc.’s next earnings report date is 08th Nov 2023.
The consensus rating of Wall Street analysts for BioLife Solutions Inc. is Strong Buy (1), with a target price of $30.57, which is +124.95% compared to the current price. The earnings rating for BioLife Solutions Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BioLife Solutions Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BioLife Solutions Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.00, ATR14 : 0.69, CCI20 : 18.61, Chaikin Money Flow : 0.01, MACD : -0.07, Money Flow Index : 55.53, ROC : 5.87, RSI : 50.98, STOCH (14,3) : 57.08, STOCH RSI : 0.46, UO : 56.29, Williams %R : -42.92), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BioLife Solutions Inc. in the last 12-months were: Aby J. Mathew (Option Excercise at a value of $82 400), Aby J. Mathew (Sold 43 870 shares of value $874 368 ), Aebersold Sarah (Option Excercise at a value of $0), Aebersold Sarah (Sold 3 342 shares of value $67 896 ), Amy DuRoss (Sold 2 600 shares of value $63 310 ), Berard Todd (Option Excercise at a value of $41 200), Berard Todd (Sold 24 397 shares of value $590 973 ), Foster Karen (Option Excercise at a value of $0), Foster Karen (Sold 4 448 shares of value $92 576 ), Greef Roderick De (Option Excercise at a value of $0), Greef Roderick De (Sold 0 shares of value $0 ), Joseph Schick (Sold 3 000 shares of value $71 550 ), Karen Foster (Sold 2 145 shares of value $44 330 ), Marcus Schulz (Sold 2 976 shares of value $66 802 ), Mathew Aby (Option Excercise at a value of $247 200), Mathew Aby (Sold 127 256 shares of value $2 718 280 ), Mathew Aby J. (Option Exercise at a value of $41 200), Mathew Aby J. (Sold 20 000 shares of value $462 900 ), Michael Rice (Sold 5 938 shares of value $122 172 ), Partners Master Fund, L.P. Casdin (Buy at a value of $4 040 373), Phillips Geraint (Sold 1 539 shares of value $31 374 ), Rice Michael (Option Excercise at a value of $0), Rice Michael (Sold 47 218 shares of value $983 790 ), Roderick De Greef (Sold 179 715 shares of value $3 916 175 ), Sarah Aebersold (Sold 1 414 shares of value $29 753 ), Schulz Marcus (Option Excercise at a value of $0), Schulz Marcus (Sold 8 038 shares of value $182 714 ), Todd Berard (Option Excercise at a value of $27 810), Todd Berard (Sold 15 674 shares of value $383 269 ), Troy Wichterman (Option Excercise at a value of $1 932), Troy Wichterman (Sold 10 631 shares of value $219 874 ), Wichterman Troy (Option Excercise at a value of $1 932), Wichterman Troy (Sold 13 951 shares of value $288 180 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.
CEO: Michael Rice
Telephone: +1 425 402-1400
Address: 3303 Monte Villa Parkway, Bothell 98021, WA, US
Number of employees: 158
Fri, 11 Aug 2023 11:50 GMT Analysts Are Bullish on Top Healthcare Stocks: BioLife Solutions (BLFS), Synlogic (SYBX)
- TipRanks. All rights reserved.Mon, 07 Aug 2023 12:55 GMT BioLife Solutions (BLFS) Gets a Buy from Craig-Hallum
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.